Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Sevelda

Showing results (31-40 of 148) with videos related to

Pageof 15
Sort By:
Gynakologisch-Geburtshilfliche Rundschau|January 1, 1993
[Ca 125 in epithelial ovarian cancers of FIGO stage I]F Nagele, C Kurz, N Vavra, et al.
Geburtshilfe Und Frauenheilkunde|August 1, 1986
[Surgical gynecologic interventions in females over 75 years of age]P Sevelda, N Vavra, H Kucera, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
The role of chemotherapy including ifosfamide for ovarian carcinoma. Austrian Collab. Ovarian Cancer Study GroupK Karrer, H Salzer, P Sevelda, et al.
Gynakologische Rundschau|January 1, 1989
[Primary irradiated adenocarcinoma of the uterine cervix]N Vavra, P Sevelda, M Barrada, et al.
Wiener Klinische Wochenschrift|January 1, 1993
[The CA-125 tumor marker in epithelial ovarian cancers of stage I]F Nagele, N Vavra, C Kurz, et al.
European Journal of Gynaecological Oncology|January 1, 1990
First experiences with intraperitoneal chemotherapy in ovarian cancerE Gitsch, P Sevelda, S Schmidl, et al.
Geburtshilfe Und Frauenheilkunde|December 1, 1985
[Postoperative radiotherapy of epithelial ovarian cancers]H Kucera, P Sevelda, H Genger, et al.
Cancer Detection and Prevention|January 1, 1986
Monitoring the cytotoxic potential of a sequential polychemotherapy (adriamycin/cisplatin-vincristine/cyclophosphamide-high dose methotrexate) in patients with advanced ovarian cancer with the tumor marker CA-125P Sevelda, C Dittrich, H Salzer, et al.
Geburtshilfe Und Frauenheilkunde|February 1, 1996
-CA-125 antigen as a prognostic factor for survival in patients with epithelial ovarian carcinoma of FIGO stage I--preliminary results-E Nagele, C Kurz, P Speiser, et al.
Gynakologische Rundschau|January 1, 1990
[A CA 12-5 prognostic score for epithelial ovarian cancers]M Klein, A Rosen, P Sevelda, et al.
Pageof 15

Showing results (31-40 of 148) with videos related to

Sort By:
Pageof 15
Gynakologisch-Geburtshilfliche Rundschau|January 1, 1993
[Ca 125 in epithelial ovarian cancers of FIGO stage I]F Nagele, C Kurz, N Vavra, et al.
Geburtshilfe Und Frauenheilkunde|August 1, 1986
[Surgical gynecologic interventions in females over 75 years of age]P Sevelda, N Vavra, H Kucera, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
The role of chemotherapy including ifosfamide for ovarian carcinoma. Austrian Collab. Ovarian Cancer Study GroupK Karrer, H Salzer, P Sevelda, et al.
Gynakologische Rundschau|January 1, 1989
[Primary irradiated adenocarcinoma of the uterine cervix]N Vavra, P Sevelda, M Barrada, et al.
Wiener Klinische Wochenschrift|January 1, 1993
[The CA-125 tumor marker in epithelial ovarian cancers of stage I]F Nagele, N Vavra, C Kurz, et al.
European Journal of Gynaecological Oncology|January 1, 1990
First experiences with intraperitoneal chemotherapy in ovarian cancerE Gitsch, P Sevelda, S Schmidl, et al.
Geburtshilfe Und Frauenheilkunde|December 1, 1985
[Postoperative radiotherapy of epithelial ovarian cancers]H Kucera, P Sevelda, H Genger, et al.
Cancer Detection and Prevention|January 1, 1986
Monitoring the cytotoxic potential of a sequential polychemotherapy (adriamycin/cisplatin-vincristine/cyclophosphamide-high dose methotrexate) in patients with advanced ovarian cancer with the tumor marker CA-125P Sevelda, C Dittrich, H Salzer, et al.
Geburtshilfe Und Frauenheilkunde|February 1, 1996
-CA-125 antigen as a prognostic factor for survival in patients with epithelial ovarian carcinoma of FIGO stage I--preliminary results-E Nagele, C Kurz, P Speiser, et al.
Gynakologische Rundschau|January 1, 1990
[A CA 12-5 prognostic score for epithelial ovarian cancers]M Klein, A Rosen, P Sevelda, et al.
Pageof 15